Barcelona, Spain, 17 July 2025 – Minoryx Therapeutics, a late-stage biotech company focused on the development of therapies for orphan central nervous system (CNS) disorders today announces that it has secured a EUR 26.9m non-dilutive grant for the development of its LERI4CNS project, which will validate leriglitazone for treating potentially lethal rare diseases affecting the CNS. The grant was given as part of the pan-European project “Important Project of Common European Interest (‘IPCEI’) Med4Cure”, of which Minoryx Therapeutics is an Associated Member.

About IPCEI Med4Cure

IPCEI Med4Cure is the first Important Project of Common European Interest (IPCEI) in the field of health, approved by the European Commission on May 28, 2024. Its goal is to promote research, innovation, and the initial industrial deployment of medical products, as well as the development of innovative pharmaceutical production processes. The initiative aims to improve drug discovery, especially for unmet medical needs such as rare diseases, and the development of more innovative and sustainable pharmaceutical production processes to strengthen the European Union’s health ecosystem.

The program brings together selected projects led by various companies in six EU Member States — including Spain — and covers the entire pharmaceutical value chain. In Spain, the program is funded by CDTI and the Ministry of Science, Innovation and Universities within the framework of the Strategic Project for Economic Recovery and Transformation in Advanced Healthcare (PERTE for Health). This initiative is included in the Spanish Recovery, Transformation and Resilience Plan, which is financed by the Next Generation EU funds, through the European Union’s Recovery and Resilience Facility (RRF)

About LERI4CNS

The LERI4CNS project aims to develop and validate disease-modifying therapies for potentially life-threatening orphan central nervous system disorders, which represent a significant unmet medical need. The project will mainly focus on the clinical validation of leriglitazone. In parallel, preclinical studies will investigate its potential for treating additional orphan CNS disorders.

Aligned with the objectives of the IPCEI Med4Cure initiative, LERI4CNS addresses critical challenges in rare disease innovation and contributes to the development of novel therapeutic solutions. Its successful implementation will allow leriglitazone to reach patients affected by rare CNS disorders, significantly improving their quality of life while reducing the burden on healthcare systems.

About Leriglitazone

Leriglitazone is Minoryx Therapeutics’ novel orally bioavailable, selective PPAR gamma agonist with a potential first-in-class and best-in-class profile for CNS diseases. It has demonstrated brain penetration and a favourable safety profile. It showed robust preclinical proof-of-concept in animal models of multiple diseases by modulating pathways leading to neuroinflammation, demyelination, mitochondrial dysfunction, oxidative stress, and axonal degeneration. There is clinical evidence for efficacy in X-ALD as well as Friedreich’s Ataxia and it is being investigated for Rett syndrome.